In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160

AIDS Research and Human Retroviruses

Volumn 12, Issue 11, 1996, Pages 1041-1051

  Pincus, Seth H ^a,i   Wehrly, Kathy ^a   Cole, Robert ^a   Fang, Hua ^a   Lewis, George K ^b   McClure, Jan ^c   Conley, Anthony J ^d   Wahren, Britta ^e   Posner, Marshall R ^f   Notkins, Abner L ^g   Tilley, Shermaine A ^h   Pinter, Abraham ^h   Eiden, Lee ^g   Teintze, Martin ⁱ   Dorward, David ^a   Tolstikov, Vladimir V ^a   Smaus, Susan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^h PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

ⁱ MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; BREFELDIN A; CORTISONE; DANSYLCADAVERINE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; IMMUNOTOXIN; MONOCLONAL ANTIBODY; NOCODAZOLE; RETINOIC ACID; SYNTHETIC PEPTIDE; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS ISOLATION;

EID: 0029776743     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.1041     Document Type: Article

References (57)

1. Pincus SH, Wehrly K, and Chesebro B: Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol 1989;142:3070-3075.
2. Pincus SH, Cole RL, Hersh EM, Lake D, Masuho Y, Durda PJ, and McClure J: In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J Immunol 1991;146:4315-4324.
3. Pincus SH and McClure J: Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Proc Natl Acad Sci USA 1993;90:332-336.
4. Till MA, Zolla-Pazner S, Gorny MK, Patton JS, Uhr JW and Vitetta ES: Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci USA 1989;86:1987-1991.
5. Till MA, Ghetie V, Gregory T, Patzer EJ, Porter JP, Uhr JW, Capon DJ, and Vitetta ES: HIV-infected cells are killed by rCD4-ricin A chain. Science 1988;242:1166-1168.
6. Tsubota H, Winkler G, Meade HM, Jakubowski A, Thomas DW, and Letvin NL: CD4-Pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro. J Clin Invest 1990;86:1684-1689.
7. Chaudhary VK, Mizukami T, Fuerst TR, FitzGerald DJ, Moss B, Pastan I, and Berger EA: Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature (London) 1988;335:369-372.
8. Berger EA, Clouse KA, Chaudhary VK, Chakrabarti S, FitzGerald DJ, Pastan I, and Moss B: CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci USA 1989;86:9539-9543.
9. Ashorn P, Moss B, Weinstein JN, Chaudhary VK, FitzGerald DJ, Pastan I, and Berger EA: Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas extoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1990;87:8889-8893.
10. Ashom P, Moss B, and Berger EA: Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins. J Acquire Immune Defic Syndr 1992;570-77.
11. - T cells in acute HIV infection in vitro. J Immunol 1993; 150:5202-5208.
12. Finberg RW, Wahl SM, Allen JB, Soman O, Strom TB, Murphy JR, and Nichols JC: Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991; 252:1703-1705.
13. Kennedy PE, Moss B, and Berger EA: Primary HIV-1 refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 1993;192:375-379.
14. Wrin T, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH: Adaptation to persistent growth in the H9 cell line renders a primary isolate of HIV-1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
15. Pincus SH and Wehrly K: AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: Implications for combination chemotherapy and immunotherapy. J Infect Dis 1990;162:1233-1238.
16. Chesebro B, Wehrly K, Nishio J, and Ferryman S: Macrophage-tropic HIV isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-6554.
17. Kabat D, Kozak SL, Wehrly K, and Chesebro B: Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of HIV. J Virol 1994;68:2570-2577.
18. Chesebro B and Wehrly K: Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 1988;62:3779-3788.
19. Pincus SH, Wehrly K, and Chesebro B: Use of a focal infectivity assay for testing susceptibility of HIV to antiviral agents. BioTechniques 1991;10:336-342.
20. Kalyanaraman VS, Rausch DM, Osborne J, Padgett M, Hwang KM, Lifson JD, and Eiden LE: Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation. J Immunol 1990;145:4072-4078.
21. Rausch DM, Lifson JD, Padgett MP, Chandrasekhar B, Lendvay J, Hwang KM, and Eiden LE: CD4(81-92)-based peptide derivatives. Biochem Pharmacol 1992;43:1785-1796.
22. Shang F, Huang H, Revesz K, Chen H-C, Herz R, and Pinter A: Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein p17: Identification of epitopes exposed at the surfaces of infected cells. J Virol 1991;65:4798-4804.
23. Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD, and Kennedy RC: Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 1986;5:3065-3071.
24. Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, and Weiss RA: Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 1988;165:209-215.
25. Sattentau QJ, Zolla-Pazner S, and Poignard P: Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995; 206:713-717.
26. Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, and Fisher G: Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 1993;91:1987-1996.
27. Jameson BA, Rao PE, Kong LI, Hahn BH, Shaw GM, Hood LE, and Kent SBH: Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein. Science 1988;240:1335-1337.
28. Clayton LK, Hussey RE, Steinbrich R, Ramachandran H, Husain Y, and Reinherz EL: Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. Nature (London) 1988;335:363-366.
29. Berger EA, Lifson JD, and Eiden LE: Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: Implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc Natl Acad Sci USA 1991;88:8082-8086.
30. Eiden LE and Lifson JD: HIV interactions with CD4: A continuum of conformations and consequences. Immunol Today 1992;13: 201-206.
31. Langejijk JPM, Puijk WC, Vanhoorn WP, and Meloen RH: Location of CD4 dimerization site explains critical role of CDR3-like region in HIV-1 infection and T-cell activation and implies a model for complex of coreceptor-MHC. J Biol Chem 1993; 268:16875-16878.
32. Daar ES, Li XL, Moudgil T, and Ho DD: High concentration of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990;87:6574-6578.
33. Brighty DW, Rosenberg M, Chen ISY, and Ivey-Hoyle M: Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci USA 1991;88:7802-7805.
34. Moore JP, McKeating JA, Huang Y, Ashkenazi A, and Ho DD: Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992;66:235-243.
35. O'Brien WA, Mao S-H, Cao Y, and Moore JP: Macrophage-tropic and T-cell line-adapted chimeric strains of HIV-1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J Virol 1994;68:5264-5269.
36. Pincus SH, McClure J, and Fang H: Use of anti-HIV immunotoxins as probes of the biology of HIV-infected cells. In: Second International Congress on Biological Response Modifiers, San Diego, California. Can J Infect Dis 1994;5(Suppl. A):23A-27A.
37. Plank C, Oberhauser B, Mechtler K, Koch C, and Wagner E: The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem 1994;269: 12918-12924.
38. Pincus SH, Messer KG, and Hu S-L: Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. J Clin Invest 1994;93:140-146.
39. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu S-L, and Smith GE: Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993; 167:533-537.
40. May RD, Finkelman FD, Wheeler HT, Uhr JW, and Vitetta ES: Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells. J Immunol 1990;144:3637-3642.
41. Hudson TH and Grillo FG: Brefeldin-A enhancement of ricin A-chain immunotoxins and blockade of intact ricin, modeccin, and abrin. J Biol Chem 1991;266:18586-18592.
42. Wu YN, Gadina M, Tao-Cheng J-H, and Youle RJ: Retinoic acid disrupts the Golgi apparatus and increases the cytosolic routing of specific protein toxins. J Cell Biol 1994;125:743-753.
43. Pal R, Mumbauer S, Hoke GM, Takatsuki A, and Sarngadharan MG: Brefeldin A inhibits the processing and secretion of envelope glycoproteins of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1991;7:707-712.
44. Hinkula J, Bratt G, Gilljam G, Nordlund S, Broliden PA, Holmberg V, Olausson-Hansson E, Albert J, Sandstrom E, and Wahren B: Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J AIDS 1994;7:940-951.
45. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, and Merigan TC: Failure of short-term CD4-PE40 infusions to reduce viral load in HIV infected individuals. J Infect Dis 1994;170:1009-1013.
46. Davey RT, Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, Cox SR, Polis MA, Kovacs JA, Falloon J, Walker RE, Salzman N, Masur H, and Lane HC: Recombinant soluble CD4-pseudomonas exotoxin, a novel immunotoxin, in the treatment of individuals infected with HIV. J Infect Dis 1994;170:1180-1188.
47. Pincus SH: Anti-HIV immunotoxins: gp41 rather than gp120 should be the target. Int Antiviral News 1994;2:147-148.
48. Letvin NL, Chalifoux LV, Reimann KA, Ritz J, Schlossman SF, and Lambert JM: In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells. J Clin Invest 1986;78:666-673.
49. Pincus SH and Tolstikov VV: Anti-human immunodeficiency virus immunoconjugates. Adv Pharmacol 1995;32:205-242.
50. Pincus SH, Stocks CJ Jr, and Ewing LP: Monoclonal anti-(T,G)-A - L antibodies: Characterization of fine specificity and idiotype expression. Mol Immunol 1982;19:1551-1559.
51. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, Roby CA, Kamin-Lewis R, and Lewis GK: Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 1994;10:371-381.
52. Broliden PA, Ljunggren K, Hinkula J, Norrby E, Akerblom L, and Wahren B: A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol 1990;64:936-940.
53. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, and Byrn RA: An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991;146:4325-4332.
54. Tilley SA, Honnen WJ, Racho ME, Hilgartner M, and Pinter A: A human monoclonal antibody against the CD4-binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res Virol 1991;142:247-259.
55. Pinter A, Honnen WJ, Racho ME, and Tilley SA: A potent neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res Hum Retroviruses 1993;9:985-996.
56. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
57. Takeda S, Dorfman NA, Robert-Guroff M, Notkins AL, and Rando RF: Two-phase approach for the expression of high affinity human anti-HIV immunoglobulin Fab domains in E. coli. Hybridoma. 1995;14:9-18.